Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 4
2015 2
2017 1
2018 2
2020 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
Chandran V, van der Heijde D, Fleischmann RM, Lespessailles E, Helliwell PS, Kameda H, Burgos-Vargas R, Erickson JS, Rathmann SS, Sprabery AT, Birt JA, Shuler CL, Gallo G. Chandran V, et al. Among authors: rathmann ss. Rheumatology (Oxford). 2020 Oct 1;59(10):2774-2784. doi: 10.1093/rheumatology/kez684. Rheumatology (Oxford). 2020. PMID: 32031665 Free PMC article. Clinical Trial.
Response to H Zeidler's comments on the CONCERTO study.
Burmester GR, Kivitz A, Kupper H, Arulmani U, Florentinus S, Goss SL, Rathmann SS, Fleischmann RM. Burmester GR, et al. Among authors: rathmann ss. Ann Rheum Dis. 2014 Aug;73(8):e51. doi: 10.1136/annrheumdis-2014-205704. Epub 2014 Jun 9. Ann Rheum Dis. 2014. PMID: 24914070 No abstract available.
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors.
Nash P, Behrens F, Orbai AM, Rathmann SS, Adams DH, Benichou O, Deodhar A. Nash P, et al. Among authors: rathmann ss. RMD Open. 2018 Sep 7;4(2):e000692. doi: 10.1136/rmdopen-2018-000692. eCollection 2018. RMD Open. 2018. PMID: 30233812 Free PMC article.
Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
van der Heijde D, Breban M, Halter D, DiVittorio G, Bratt J, Cantini F, Kary S, Pangan AL, Kupper H, Rathmann SS, Sieper J, Mease PJ. van der Heijde D, et al. Among authors: rathmann ss. Rheumatology (Oxford). 2015 Jul;54(7):1210-9. doi: 10.1093/rheumatology/keu438. Epub 2014 Dec 25. Rheumatology (Oxford). 2015. PMID: 25541333 Free PMC article. Clinical Trial.